| scholarly article | Q13442814 |
| P50 | author | Olivier-François Couturier | Q91942624 |
| P2093 | author name string | Caroline Rousseau | |
| Jean-Yves Pierga | |||
| Alexandre Cochet | |||
| Pierre Vera | |||
| Pierre Olivier | |||
| Jean-Louis Alberini | |||
| Sylvie Girault | |||
| Anne-Laure Martin | |||
| Emmanuelle Fourme | |||
| Pierre Lovinfosse | |||
| Florent Cachin | |||
| Franck Lacœuille | |||
| Lionel Uwer | |||
| Jérome Lemonnier | |||
| Francis Bouchet | |||
| Christel Mesleard | |||
| Benoit Scarwell | |||
| P2860 | cites work | The role of dual time point FDG PET imaging in the evaluation of solitary pulmonary nodules with an initial standard uptake value less than 2.5. | Q53246320 |
| Imaging early changes in proliferation at 1 week post chemotherapy: a pilot study in breast cancer patients with 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography. | Q53496753 | ||
| Molecular imaging of proliferation in malignant lymphoma. | Q53512276 | ||
| Relative activities of thymidylate synthetase and thymidine kinase in 1,2-dimethylhydrazine-induced colon carcinomas in rats. | Q53530520 | ||
| Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. | Q54117465 | ||
| Thymidine transport by Novikoff rat hepatoma cells synchronized by double hydroxyurea treatment. | Q54527565 | ||
| Dual time point fluorine-18 fluorodeoxyglucose positron emission tomography: a potential method to differentiate malignancy from inflammation and normal tissue in the head and neck | Q73132899 | ||
| DNA-synthesis enzyme activity: a biological tool useful for predicting anti-metabolic drug sensitivity in breast cancer? | Q73302860 | ||
| How Long of a Dynamic 3'-Deoxy-3'-[18F]fluorothymidine ([18F]FLT) PET Acquisition Is Needed for Robust Kinetic Analysis in Breast Cancer? | Q89483641 | ||
| Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis | Q31950730 | ||
| 3'-[18F]fluoro-3'-deoxythymidine ([18F]-FLT) as positron emission tomography tracer for imaging proliferation in a murine B-Cell lymphoma model and in the human disease. | Q34197349 | ||
| FLT: measuring tumor cell proliferation in vivo with positron emission tomography and 3'-deoxy-3'-[18F]fluorothymidine | Q34699233 | ||
| From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors | Q34978457 | ||
| In vivo imaging of cellular proliferation in colorectal cancer using positron emission tomography | Q35596074 | ||
| Biological characterisation of breast cancer by means of PET. | Q35764576 | ||
| Fluorinated tracers for imaging cancer with positron emission tomography | Q35829825 | ||
| The value of dual-time-point18F-FDG PET/CT for identifying axillary lymph node metastasis in breast cancer patients | Q36324071 | ||
| When should we recommend use of dual time-point and delayed time-point imaging techniques in FDG PET? | Q38077707 | ||
| [18F]3'-deoxy-3'-fluorothymidine PET for the diagnosis and grading of brain tumors | Q38515063 | ||
| Evaluation of thoracic tumors with 18F-fluorothymidine and 18F-fluorodeoxyglucose-positron emission tomography | Q40350756 | ||
| Metabolism of 3'-deoxy-3'-[F-18]fluorothymidine in proliferating A549 cells: validations for positron emission tomography | Q40508408 | ||
| Basis of FLT as a cell proliferation marker: comparative uptake studies with [3H]thymidine and [3H]arabinothymidine, and cell-analysis in 22 asynchronously growing tumor cell lines | Q40740784 | ||
| Nucleoside transport in normal and neoplastic cells | Q40837882 | ||
| Dual-time-point [18F]-FDG PET/CT in the diagnostic evaluation of suspicious breast lesions. | Q43217785 | ||
| Radiopharmaceuticals XXVII. 18F-labeled 2-deoxy-2-fluoro-d-glucose as a radiopharmaceutical for measuring regional myocardial glucose metabolism in vivo: tissue distribution and imaging studies in animals | Q43534031 | ||
| 3-deoxy-3-[(18)F]fluorothymidine-positron emission tomography for noninvasive assessment of proliferation in pulmonary nodules. | Q44030329 | ||
| Dual time point 18F-FDG PET for the evaluation of pulmonary nodules. | Q44050019 | ||
| Evaluation of pyrimidine metabolising enzymes and in vitro uptake of 3'-[(18)F]fluoro-3'-deoxythymidine ([(18)F]FLT) in pancreatic cancer cell lines. | Q44112084 | ||
| Rat studies comparing 11C-FMAU, 18F-FLT, and 76Br-BFU as proliferation markers. | Q44240339 | ||
| [18F]FLT PET for diagnosis and staging of thoracic tumours | Q44536500 | ||
| Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG. | Q44576349 | ||
| PET with [18F]fluorothymidine for imaging of primary breast cancer: a pilot study | Q44780804 | ||
| Detection and grading of soft tissue sarcomas of the extremities with (18)F-3'-fluoro-3'-deoxy-L-thymidine. | Q44795401 | ||
| Diagnostic performance of dual-time 18F-FDG PET in the diagnosis of pulmonary nodules: a meta-analysis | Q44962853 | ||
| [18F]3'-deoxy-3'-fluorothymidine-PET in NHL patients: whole-body biodistribution and imaging of lymphoma manifestations--a pilot study | Q45082810 | ||
| Comparison of 18F-FLT PET and 18F-FDG PET in esophageal cancer. | Q45305156 | ||
| Accuracy of early and delayed FDG PET-CT and of contrast-enhanced CT in the evaluation of lung nodules: a preliminary study on 30 patients. | Q45939044 | ||
| Tumor 3'-deoxy-3'-(18)F-fluorothymidine ((18)F-FLT) uptake by PET correlates with thymidine kinase 1 expression: static and kinetic analysis of (18)F-FLT PET studies in lung tumors | Q46104674 | ||
| Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG. | Q46270281 | ||
| Dual-time-point 18F-FDG PET/CT versus dynamic breast MRI of suspicious breast lesions | Q46305175 | ||
| The uptake of 3'-deoxy-3'-[18F]fluorothymidine into L5178Y tumours in vivo is dependent on thymidine kinase 1 protein levels | Q46404885 | ||
| Dual-phase 18F-FDG PET in the diagnosis of pulmonary nodules with an initial standard uptake value less than 2.5. | Q46468379 | ||
| Breast cancer with low FDG uptake: characterization by means of dual-time point FDG-PET/CT. | Q46659070 | ||
| Quantification of cellular proliferation in tumor and normal tissues of patients with breast cancer by [18F]fluorothymidine-positron emission tomography imaging: evaluation of analytical methods | Q46788429 | ||
| Positron emission tomography in patients with breast cancer using (18)F-3'-deoxy-3'-fluoro-l-thymidine ((18)F-FLT)-a pilot study | Q46790235 | ||
| Potential of dual-time-point imaging to improve breast cancer diagnosis with (18)F-FDG PET. | Q46790517 | ||
| Usefulness of 3'-[F-18]fluoro-3'-deoxythymidine with positron emission tomography in predicting breast cancer response to therapy. | Q46872269 | ||
| Impact of dual-time-point (18)F-FDG PET imaging and partial volume correction in the assessment of solitary pulmonary nodules | Q46948766 | ||
| PET imaging of estrogen receptors as a diagnostic tool for breast cancer patients presenting with a clinical dilemma. | Q50594305 | ||
| FDG PET/CT during neoadjuvant chemotherapy may predict response in ER-positive/HER2-negative and triple negative, but not in HER2-positive breast cancer. | Q53120559 | ||
| Diagnostic accuracy of dual-time-point 18F-FDG PET/CT for the detection of axillary lymph node metastases in breast cancer patients. | Q53163580 | ||
| P433 | issue | 1 | |
| P304 | page(s) | 109 | |
| P577 | publication date | 2019-12-12 | |
| P1433 | published in | EJNMMI Research | Q27723773 |
| P1476 | title | Dual time point [18F]FLT-PET for differentiating proliferating tissues vs non-proliferating tissues | |
| P478 | volume | 9 |
Search more.